Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News WPD Pharmaceuticals Inc C.WBIO

Alternate Symbol(s):  WPDPF

Industrials Technology
WPD Pharmaceuticals Inc. is a Canada-based clinical-stage pharmaceutical company, with a focus on glioblastoma cancer (GBM) and other brain tumor programs. The Company is a biotechnology research and development company with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules. It has four novel drug candidates with one in... see more

Recent & Breaking News (CSE:WBIO)

WPD Pharmaceuticals Licensor Granted Another Key Patent for the Development of WPD101 Drug Candidate

GlobeNewswire May 28, 2020

IIROC Trade Resumption - WBIO

Canada NewsWire May 15, 2020

WPD Pharmaceuticals To Resume Trading

GlobeNewswire May 15, 2020

WPD Pharmaceuticals Comments on SEC Order

GlobeNewswire May 5, 2020

IIROC Trading Halt - WBIO

Canada NewsWire May 4, 2020

WPD Pharmaceuticals and CNS Pharmaceuticals Identify Leading Polish Medical Institutions for Berubicin Phase 2 Clinical Trial

GlobeNewswire April 30, 2020

CNS Pharmaceuticals and WPD Pharmaceuticals Identify Leading Polish Medical Institutions for Berubicin Phase 2 Clinical Trial

PR Newswire April 30, 2020

WPD Pharmaceutical's Annamycin Drug Approved for Accelerated European Clinical Trial

GlobeNewswire April 29, 2020

WPD Pharmaceuticals Announces FDA Application Under The Orphan Drug Act Was Submitted By License Partner for Brain Cancer Drug, Berubicin

GlobeNewswire April 24, 2020

WPD Pharmaceuticals' Annamycin Drug Candidate Meets Endpoint in Successful U.S. Phase 1 AML Trial With No Evidence of Cardiotoxicity

GlobeNewswire April 23, 2020

WPD Pharmaceuticals and CNS Pharmaceuticals Announce Additional Coronavirus Testing on WP1122 by ImQuest Biosciences

GlobeNewswire April 21, 2020

WPD Pharmaceuticals' License Partner, Moleculin Biotech to Host Conference Call to Discuss COVID-19 Potential in WP1122 Drug Candidate

GlobeNewswire April 16, 2020

CNS Pharmaceuticals Announces Independent University Research Confirms Active Compound in WP1122 Completely Prevents Coronavirus Replication In Vitro; WP1122 is Subject to Development Agreement with WPD Pharmaceuticals

PR Newswire April 13, 2020

WPD Pharmaceuticals to Resume Trading on Monday, April 13, 2020

GlobeNewswire April 13, 2020

IIROC Trade Resumption - WBIO

Canada NewsWire April 9, 2020

WPD Pharmaceuticals Clarifies News on Licensed Drug Candidate

GlobeNewswire April 9, 2020

IIROC Trading Halt - WBIO

Canada NewsWire April 9, 2020

WPD Pharmaceuticals Reports Active Compound in Licensed Drug Candidate Reduces Coronavirus Replication in Vitro by 100%

GlobeNewswire April 9, 2020

WPD Pharmaceuticals Provides Corporate Update

GlobeNewswire April 8, 2020

WPD Pharmaceuticals Welcome Dr. Waldemar Debinski to its Scientific Advisory Board

GlobeNewswire April 1, 2020